Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access enfortumab vedotin for advanced urothelial carcinoma in Japan
jRCT2031210099Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Open-label, single-arm trial of enfortumab vedotin in transitional cell carcinoma (TCC), sponsored by Astellas Pharma. Primary endpoints: Adverse events and Serious adverse events. Started Jul 2021; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2031210099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210099.